Dataset Information


Pharmacologic treatment for urgency-predominant urinary incontinence in women diagnosed using a simplified algorithm: a randomized trial.



The purpose of this study was to evaluate clinical outcomes associated with the initiation of treatment for urgency-predominant incontinence in women diagnosed by a simple 3-item questionnaire.

Study design

We conducted a multicenter, double-blinded, 12-week randomized trial of pharmacologic therapy for urgency-predominant incontinence in ambulatory women diagnosed by the simple 3-item questionnaire. Participants (N = 645) were assigned randomly to fesoterodine therapy (4-8 mg daily) or placebo. Urinary incontinence was assessed with the use of voiding diaries; postvoid residual volume was measured after treatment.


After 12 weeks, women who had been assigned randomly to fesoterodine therapy reported 0.9 fewer urgency and 1.0 fewer total incontinence episodes/day, compared with placebo (P ? .001). Four serious adverse events occurred in each group, none of which was related to treatment. No participant had postvoid residual volume of ? 250 mL after treatment.


Among ambulatory women with urgency-predominant incontinence diagnosed with a simple 3-item questionnaire, pharmacologic therapy resulted in a moderate decrease in incontinence frequency without increasing significant urinary retention or serious adverse events, which provides support for a streamlined algorithm for diagnosis and treatment of female urgency-predominant incontinence.


PROVIDER: S-EPMC3570031 | BioStudies | 2012-01-01

REPOSITORIES: biostudies

Similar Datasets

2013-01-01 | S-EPMC4019400 | BioStudies
2019-01-01 | S-EPMC6946395 | BioStudies
1000-01-01 | S-EPMC3969610 | BioStudies
2020-01-01 | S-EPMC7076894 | BioStudies
2020-01-01 | S-EPMC7754378 | BioStudies
2014-01-01 | S-EPMC4265241 | BioStudies
2020-01-01 | S-EPMC6923600 | BioStudies
2018-01-01 | S-EPMC6059366 | BioStudies
2009-01-01 | S-EPMC2705818 | BioStudies
2013-01-01 | S-EPMC3679189 | BioStudies